{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:11:41Z","timestamp":1783923101877,"version":"3.55.0"},"reference-count":209,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,19]],"date-time":"2027-05-19T00:00:00Z","timestamp":1810684800000},"content-version":"am","delay-in-days":260,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1CA269607"],"award-info":[{"award-number":["RO1CA269607"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bcp.2026.118058","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:25:36Z","timestamp":1778858736000},"page":"118058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Nanoparticle-Based delivery of proteasome inhibitors for glioblastoma Therapy: Strategies to overcome Blood-Brain barrier and therapeutic resistance"],"prefix":"10.1016","volume":"251","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6649-3694","authenticated-orcid":false,"given":"Md Ataur","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh Kumar","family":"Yadab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsanul Hoque","family":"Apu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meser M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.bcp.2026.118058_b0005","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: a clinical review","volume":"310","author":"Omuro","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2026.118058_b0010","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418790452","article-title":"Treatment of glioblastoma in adults","volume":"11","author":"Wick","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0015","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s12672-025-02567-3","article-title":"Glioblastoma multiforme: an updated overview of temozolomide resistance mechanisms and strategies to overcome resistance","volume":"16","author":"Pu","year":"2025","journal-title":"Discov. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118058_b0020","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/cells14060407","article-title":"Angiogenesis in glioblastoma\u2014treatment approaches","volume":"14","author":"Nowacka","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s13402-025-01149-3","article-title":"Targeting VCP with V8 suppresses glioblastoma development via formation of aggregates and disruption of mitophagy flux","volume":"49","author":"Cao","year":"2026","journal-title":"Cell. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev-biochem-061516-044908","article-title":"Proteasomal and autophagic degradation systems","volume":"86","author":"Dikic","year":"2017","journal-title":"Annu. Rev. Biochem"},{"issue":"7","key":"10.1016\/j.bcp.2026.118058_b0035","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc1121","article-title":"Molecular mechanisms of glioma invasiveness: the role of proteases","volume":"3","author":"Rao","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2026.118058_b0040","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.3390\/cells10123465","article-title":"Killing by degradation: regulation of apoptosis by the ubiquitin-proteasome-system","volume":"10","author":"Abbas","year":"2021","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.bcp.2026.118058_b0045","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/13543784.2020.1803827","article-title":"Proteasome inhibition for the treatment of glioblastoma","volume":"29","author":"Roth","year":"2020","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.bcp.2026.118058_b0050","unstructured":"Workman, P. Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. Cold Spring Harbor Laboratory Press."},{"issue":"2","key":"10.1016\/j.bcp.2026.118058_b0055","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3390\/ijms22020888","article-title":"Pathological mechanisms of bortezomib-induced peripheral neuropathy","volume":"22","author":"Yamamoto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2026.118058_b0060","doi-asserted-by":"crossref","first-page":"9676","DOI":"10.3390\/curroncol30110702","article-title":"Proteasome inhibitors against glioblastoma\u2014Overview of molecular mechanisms of cytotoxicity, progress in clinical trials, and perspective for use in personalized medicine","volume":"30","author":"Gozdz","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bcp.2026.118058_b0065","series-title":"Biotechnological Advances in Healthomics","first-page":"411","article-title":"Marine-Derived Anticancer Agents: Synergizing Omics and Biotechnology for Breakthroughs","author":"Washikur","year":"2026"},{"issue":"3","key":"10.1016\/j.bcp.2026.118058_b0070","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3390\/ijms22031318","article-title":"Deciphering the role of autophagy in treatment of resistance mechanisms in glioblastoma","volume":"22","author":"Khan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0075","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/ph19010094","article-title":"Nanomedicine-Driven Therapeutic strategies for Rheumatoid Arthritis-Associated Depression: Mechanisms and Pharmacological Progress","volume":"19","author":"Hu","year":"2026","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.bcp.2026.118058_b0080","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.3390\/ijms24032496","article-title":"Recent advances on surface-modified GBM targeted nanoparticles: targeting strategies and surface characterization","volume":"24","author":"Rod\u00e0","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.118058_b0085","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3390\/cancers13040670","article-title":"Recent advancements in stimuli responsive drug delivery platforms for active and passive cancer targeting","volume":"13","author":"Rahim","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2026.118058_b0090","doi-asserted-by":"crossref","first-page":"8483","DOI":"10.2147\/IJN.S148359","article-title":"Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy","author":"Zhang","year":"2017","journal-title":"Int. J. Nanomed."},{"issue":"3","key":"10.1016\/j.bcp.2026.118058_b0095","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2174\/0929867328666210902141257","article-title":"Gold nanoparticles in triple-negative breast cancer therapeutics","volume":"30","author":"Akter","year":"2023","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0100","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/biom11010060","article-title":"The ubiquitin\u2013proteasome system in immune cells","volume":"11","author":"\u00c7etin","year":"2021","journal-title":"Biomolecules"},{"issue":"21","key":"10.1016\/j.bcp.2026.118058_b0105","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.3390\/molecules26216682","article-title":"Structural diversity of ubiquitin E3 ligase","volume":"26","author":"Toma-Fukai","year":"2021","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.bcp.2026.118058_b0110","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s13402-023-00777-x","article-title":"E3 ubiquitin ligases in cancer stem cells: key regulators of cancer hallmarks and novel therapeutic opportunities","volume":"46","author":"Zou","year":"2023","journal-title":"Cell. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0115","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1146\/annurev.bi.65.070196.004101","article-title":"Structure and functions of the 20S and 26S proteasomes","volume":"65","author":"Coux","year":"1996","journal-title":"Annu. Rev. Biochem"},{"issue":"5","key":"10.1016\/j.bcp.2026.118058_b0120","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/biom9050190","article-title":"The contribution of the 20S proteasome to proteostasis","volume":"9","author":"Kumar Deshmukh","year":"2019","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.bcp.2026.118058_b0125","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41580-025-00870-z","article-title":"Degrons: defining the rules of protein degradation","volume":"26","author":"Zhang","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118058_b0130","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1007\/s12035-021-02339-4","article-title":"The role of the ubiquitin proteasome system in glioma: analysis emphasizing the main molecular players and therapeutic strategies identified in glioblastoma multiforme","volume":"58","author":"Maksoud","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2026.118058_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.574011","article-title":"Targeting the ubiquitin system in glioblastoma","volume":"10","author":"Scholz","year":"2020","journal-title":"Front. Oncol."},{"issue":"15","key":"10.1016\/j.bcp.2026.118058_b0140","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2174\/1381612826666200131100630","article-title":"Wnt\/beta-catenin and PI3K\/Akt\/mTOR signaling pathways in glioblastoma: two main targets for drug design: a review","volume":"26","author":"Shahcheraghi","year":"2020","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.bcp.2026.118058_b0145","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/15384101.2019.1706903","article-title":"The double dealing of cyclin D1","volume":"19","author":"Tchakarska","year":"2020","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0150","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1186\/s12964-025-02112-3","article-title":"The multifaceted role of PUMA in cell death pathways: its therapeutic potential across cancer types","volume":"23","author":"Tat","year":"2025","journal-title":"Cell Commun. Signaling"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0155","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s11658-024-00682-7","article-title":"Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer","volume":"30","author":"Zhang","year":"2025","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"9","key":"10.1016\/j.bcp.2026.118058_b0160","doi-asserted-by":"crossref","first-page":"8441","DOI":"10.3390\/ijms24098441","article-title":"Ubiquitination links DNA damage and repair signaling to cancer metabolism","volume":"24","author":"Koo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.bcp.2026.118058_b0165","doi-asserted-by":"crossref","first-page":"5632","DOI":"10.3390\/cancers15235632","article-title":"Targeting proteasomes and the MHC class I antigen presentation machinery to treat cancer, infections and age-related diseases","volume":"15","author":"Rana","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2026.118058_b0170","doi-asserted-by":"crossref","unstructured":"Ho Zhi Guang, M., et al., Targeting proteotoxic stress in cancer: a review of the role that protein quality control pathways play in oncogenesis. Cancers, 2019. 11(1): p. 66.","DOI":"10.3390\/cancers11010066"},{"issue":"3","key":"10.1016\/j.bcp.2026.118058_b0175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bcp.2026.118058_b0180","doi-asserted-by":"crossref","unstructured":"Muz, B., et al., Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug design, development and therapy, 2016: p. 217-226.","DOI":"10.2147\/DDDT.S93602"},{"issue":"3","key":"10.1016\/j.bcp.2026.118058_b0185","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12185-016-2016-0","article-title":"Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma","volume":"104","author":"Ri","year":"2016","journal-title":"Int. J. Hematol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118058_b0190","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s43440-020-00081-7","article-title":"Natural products as promising targets in glioblastoma multiforme: a focus on NF-\u03baB signaling pathway","volume":"72","author":"Soukhtanloo","year":"2020","journal-title":"Pharmacol. Rep."},{"issue":"13","key":"10.1016\/j.bcp.2026.118058_b0195","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.3390\/cancers15133458","article-title":"Emerging role of glioma stem cells in mechanisms of therapy resistance","volume":"15","author":"Eckerdt","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.bcp.2026.118058_b0200","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood\u2013brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bcp.2026.118058_b0205","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1081\/CNV-120030218","article-title":"Development of the proteasome inhibitor Velcade\u2122(Bortezomib)","volume":"22","author":"Adams","year":"2004","journal-title":"Cancer Invest."},{"issue":"7","key":"10.1016\/j.bcp.2026.118058_b0210","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118058_b0215","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41419-021-03701-z","article-title":"Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib","volume":"12","author":"Shen","year":"2021","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.bcp.2026.118058_b0220","first-page":"893","article-title":"Carfilzomib","volume":"121","author":"Kortuem","year":"2013","journal-title":"Blood, the Journal of the American Society of Hematology"},{"issue":"3","key":"10.1016\/j.bcp.2026.118058_b0225","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/10428194.2018.1523398","article-title":"Ixazomib\u2013the first oral proteasome inhibitor","volume":"60","author":"Xie","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcp.2026.118058_b0230","doi-asserted-by":"crossref","unstructured":"Gupta, N., et al., Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor: N. Gupta et al. Clinical pharmacokinetics, 2019. 58(4): p. 431-449.","DOI":"10.1007\/s40262-018-0702-1"},{"key":"10.1016\/j.bcp.2026.118058_b0235","doi-asserted-by":"crossref","unstructured":"Miller, C.P., et al., The Novel, Orally Active Proteasome Inhibitor, NPI-0052, Induces Apoptosis in Leukemia Lymphoma Cell Lines and Patient Specimens. 2005, American Society of Hematology.","DOI":"10.1182\/blood.V106.11.241.241"},{"issue":"6","key":"10.1016\/j.bcp.2026.118058_b0240","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/neuonc\/nov299","article-title":"Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier","volume":"18","author":"Di","year":"2016","journal-title":"Neuro Oncol."},{"issue":"19","key":"10.1016\/j.bcp.2026.118058_b0245","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.3390\/ijms26199418","article-title":"Navigating the Central nervous System (CNS): a Pharmacokinetic Approach to the Treatment of CNS Tumors, Glioblastoma Multiforme (GBM), in Particular","volume":"26","author":"Bartusik-Aebisher","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118058_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1641752","article-title":"Chemotherapeutic nanoparticles for glioblastoma","volume":"15","author":"Messina","year":"2025","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118058_b0255","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/13543776.2023.2272648","article-title":"Proteasome inhibitors as anticancer agents","volume":"33","author":"Gazzaroli","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bcp.2026.118058_b0260","first-page":"1","article-title":"Marizomib in the therapy of brain tumors\u2014how far did we go and where do we stand?","author":"Kusaczuk","year":"2025","journal-title":"Pharmacol. Rep."},{"issue":"9","key":"10.1016\/j.bcp.2026.118058_b0265","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/neuonc\/noae053","article-title":"Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial","volume":"26","author":"Roth","year":"2024","journal-title":"Neuro Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118058_b0270","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11912-020-00931-w","article-title":"Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management","volume":"22","author":"Wu","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2026.118058_b0275","first-page":"167","article-title":"Safety of proteasome inhibitors for treatment of multiple myeloma","volume":"16","author":"Schlafer","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"8","key":"10.1016\/j.bcp.2026.118058_b0280","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.tips.2023.05.006","article-title":"Overcoming proteasome inhibitor resistance in the immunotherapy era","volume":"44","author":"Patino-Escobar","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.118058_b0285","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13321","article-title":"Proton pump inhibitors display anti\u2010tumour potential in glioma","volume":"56","author":"Li","year":"2023","journal-title":"Cell Prolif."},{"key":"10.1016\/j.bcp.2026.118058_b0290","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/DDDT.S285852","article-title":"Current status and perspectives of protease inhibitors and their combination with nanosized drug delivery systems for targeted cancer therapy","author":"Rudzi\u0144ska","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2026.118058_b0295","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/cancers17040701","article-title":"Progress in drug delivery systems based on nanoparticles for improved glioblastoma therapy: addressing challenges and investigating opportunities","volume":"17","author":"Rahman","year":"2025","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.bcp.2026.118058_b0300","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1039\/C8CS00805A","article-title":"Emerging blood\u2013brain-barrier-crossing nanotechnology for brain cancer theranostics","volume":"48","author":"Tang","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bcp.2026.118058_b0305","first-page":"1","article-title":"Advancements in nanotechnology for PARP inhibitor delivery: a comprehensive review of diverse nanosystems, their mechanisms, and therapeutic applications across cancer and beyond","author":"Abualsoud","year":"2025","journal-title":"J. Biomater. Sci. Polym. Ed."},{"issue":"8","key":"10.1016\/j.bcp.2026.118058_b0310","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3390\/biomedicines12081822","article-title":"Current non-metal nanoparticle-based therapeutic approaches for glioblastoma treatment","volume":"12","author":"Gawel","year":"2024","journal-title":"Biomedicines"},{"issue":"18","key":"10.1016\/j.bcp.2026.118058_b0315","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202101454","article-title":"Nanoparticulation of prodrug into medicines for cancer therapy","volume":"8","author":"Zhang","year":"2021","journal-title":"Adv. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118058_b0320","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020279","article-title":"Transferrin Receptor-Targeted Nanocarriers: Overcoming Barriers to Treat Glioblastoma","volume":"14","author":"Ramalho","year":"2022","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.bcp.2026.118058_b0325","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3390\/ijms26051814","article-title":"Nanotherapy of Glioblastoma\u2014Where Hope grows","volume":"26","author":"Grzegorzewski","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118058_b0330","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.2147\/IJN.S243155","article-title":"PAMAM dendrimer nanomolecules utilized as drug delivery systems for potential treatment of glioblastoma: a systematic review","author":"Fana","year":"2020","journal-title":"Int. J. Nanomed."},{"issue":"38","key":"10.1016\/j.bcp.2026.118058_b0335","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202503700","article-title":"Lipid\u2010like Carbon\u2010Dot Liposomes for Enhanced Drug delivery and Membrane Fluidity Modulation in the Treatment of Metastatic Triple\u2010Negative Breast Cancer","volume":"21","author":"Lin","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.bcp.2026.118058_b0340","series-title":"Pharmacokinetics and Pharmacodynamics of Novel Drug Delivery Systems: from Basic Concepts to Applications: A Machine-Generated Literature Overview","first-page":"275","article-title":"Clinical applications of Pharmacokinetic and Pharmacodynamic Studies of Targeted Novel Drug delivery Systems","author":"Gharat","year":"2024"},{"key":"10.1016\/j.bcp.2026.118058_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100663","article-title":"Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance","volume":"48","author":"Narayanan","year":"2020","journal-title":"Drug Resist. Updat."},{"issue":"8","key":"10.1016\/j.bcp.2026.118058_b0350","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1080\/10428194.2016.1263842","article-title":"Phase I\/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma","volume":"58","author":"Vogl","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcp.2026.118058_b0355","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","author":"Bozzuto","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bcp.2026.118058_b0360","series-title":"Application of Nanotechnology in Drug Delivery","first-page":"1","article-title":"Liposomes as potential Drug Carrier Systems for Drug","author":"\u00c7a\u011fda\u015f","year":"2014"},{"issue":"8","key":"10.1016\/j.bcp.2026.118058_b0365","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3390\/pharmaceutics17081074","article-title":"Anti-PEG antibodies and their biological impact on PEGylated drugs: challenges and strategies for optimization","volume":"17","author":"Fu","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0370","doi-asserted-by":"crossref","DOI":"10.1080\/14686996.2025.2554048","article-title":"Nanocarriers based therapy and diagnosis of brain diseases: cross the blood-brain barrier","volume":"26","author":"An","year":"2025","journal-title":"Sci. Technol. Adv. Mater."},{"issue":"15","key":"10.1016\/j.bcp.2026.118058_b0375","doi-asserted-by":"crossref","first-page":"14191","DOI":"10.1021\/acsanm.3c02122","article-title":"Transferrin-conjugated PLGA nanoparticles for co-delivery of temozolomide and bortezomib to glioblastoma cells","volume":"6","author":"Ramalho","year":"2023","journal-title":"ACS Appl. Nano Mater."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0380","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"19","key":"10.1016\/j.bcp.2026.118058_b0385","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.3390\/app12199479","article-title":"Polymeric nanoparticles\u2014tools in a drug delivery system in selected cancer therapies","volume":"12","author":"Madej","year":"2022","journal-title":"Appl. Sci."},{"issue":"42","key":"10.1016\/j.bcp.2026.118058_b0390","doi-asserted-by":"crossref","first-page":"28502","DOI":"10.1021\/acsnano.4c09800","article-title":"Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment","volume":"18","author":"Wu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.bcp.2026.118058_b0395","series-title":"Ligands for Targeted Drug Delivery","first-page":"159","article-title":"Ligand conjugation strategies","author":"Kumari","year":"2025"},{"key":"10.1016\/j.bcp.2026.118058_b0400","doi-asserted-by":"crossref","DOI":"10.1080\/14737140.2025.2610261","article-title":"The importance of autophagy in multiple myeloma","author":"Bednarczyk","year":"2026","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"22","key":"10.1016\/j.bcp.2026.118058_b0405","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.3390\/polym15224369","article-title":"Dendrimers: exploring their wide structural variety and applications","volume":"15","author":"P\u00e9rez-Ferreiro","year":"2023","journal-title":"Polymers"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0410","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s42269-025-01309-3","article-title":"Development of Angiopep-2 targeted dendrimer-based nanotheranostic system for enhanced temozolomide delivery to glioblastoma multiforme","volume":"49","author":"Parashar","year":"2025","journal-title":"Bull. Natl. Res. Cent."},{"issue":"6","key":"10.1016\/j.bcp.2026.118058_b0415","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.3390\/ijms24065430","article-title":"A Glimpse into dendrimers integration in cancer imaging and theranostics","volume":"24","author":"Cruz","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118058_b0420","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.actbio.2020.11.036","article-title":"Cobalt oxide nanoparticle-synergized protein degradation and phototherapy for enhanced anticancer therapeutics","volume":"121","author":"Huang","year":"2021","journal-title":"Acta Biomater."},{"issue":"4","key":"10.1016\/j.bcp.2026.118058_b0425","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1166\/jbn.2014.1743","article-title":"Enhancing proteasome-inhibitor effect by functionalized gold nanoparticles","volume":"10","author":"Coelho","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.bcp.2026.118058_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2024.114328","article-title":"Dual-targeted TfRA4-DNA1-Ag@ AuNPs: an innovative radiosensitizer for enhancing radiotherapy in glioblastoma multiforme","volume":"245","author":"Kan","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.bcp.2026.118058_b0435","first-page":"1","article-title":"Evaluation of anticancer efficacy of survivin si-RNA functionalized combined drug-loaded mesoporous silica nanoparticles in a lung cancer mouse model","author":"Dilnawaz","year":"2025","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118058_b0440","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/IJN.S504629","article-title":"Design of pH-responsive nanomaterials based on the tumor microenvironment","author":"Liu","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"7","key":"10.1016\/j.bcp.2026.118058_b0445","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/17425247.2021.1888926","article-title":"Recent advances in iron oxide nanoparticles for brain cancer theranostics: from in vitro to clinical applications","volume":"18","author":"Sheervalilou","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.bcp.2026.118058_b0450","series-title":"Nanopesticides: from Research and Development to Mechanisms of Action and Sustainable Use in Agriculture","first-page":"227","article-title":"Environmental toxicity of nanopesticides against non-target organisms: the state of the art","author":"C\u00f4a","year":"2020"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0455","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12951-025-03352-8","article-title":"Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies","volume":"23","author":"Mehdizadeh","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118058_b0460","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1158\/1078-0432.CCR-18-2363","article-title":"Exosome-transmitted PSMA3 and PSMA3-AS1 promote proteasome inhibitor resistance in multiple myeloma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2026.118058_b0465","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/cells12101416","article-title":"Current strategies for exosome cargo loading and targeting delivery","volume":"12","author":"Zeng","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0470","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s13287-022-03212-4","article-title":"Mesenchymal stem cell-derived exosomes as a new therapeutic strategy in the brain tumors","volume":"13","author":"Ghasempour","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.bcp.2026.118058_b0475","article-title":"Current research of novel nano-delivery carriers based on exosomes: preparation, targeted enhancement, delivery mechanism and clinical application","author":"Zhu","year":"2026","journal-title":"J. Mater. Chem. B"},{"issue":"4","key":"10.1016\/j.bcp.2026.118058_b0480","doi-asserted-by":"crossref","first-page":"e1976","DOI":"10.1002\/wnan.1976","article-title":"Stemness, invasion, and immunosuppression modulation in recurrent glioblastoma using nanotherapy","volume":"16","author":"Sarkar","year":"2024","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0485","doi-asserted-by":"crossref","first-page":"e1527","DOI":"10.1002\/wnan.1527","article-title":"Stimuli\u2010responsive nanotherapeutics for precision drug delivery and cancer therapy","volume":"11","author":"Qiao","year":"2019","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118058_b0490","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.3390\/polym17121640","article-title":"A Review on the recent Advancements of Polymer-Modified Mesoporous Silica Nanoparticles for Drug delivery under Stimuli-Trigger","volume":"17","author":"Santhamoorthy","year":"2025","journal-title":"Polymers"},{"issue":"8","key":"10.1016\/j.bcp.2026.118058_b0495","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1039\/D4TB02083A","article-title":"Mechanistic understanding of pH as a driving force in cancer therapeutics","volume":"13","author":"Pandey","year":"2025","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.bcp.2026.118058_b0500","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.phrs.2016.01.029","article-title":"Oxidative stress and proteasome inhibitors in multiple myeloma","volume":"105","author":"Lipchick","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"22","key":"10.1016\/j.bcp.2026.118058_b0505","doi-asserted-by":"crossref","first-page":"14145","DOI":"10.1021\/acsnano.3c03409","article-title":"Matrix metalloproteinase-and pH-sensitive nanoparticle system enhances drug retention and penetration in glioblastoma","volume":"18","author":"Dosta","year":"2024","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.bcp.2026.118058_b0510","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.7150\/thno.40298","article-title":"Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2026.118058_b0515","doi-asserted-by":"crossref","first-page":"9597","DOI":"10.2147\/IJN.S531451","article-title":"Advances and challenges in Nano-delivery Systems for Glioblastoma Treatment: a Comprehensive Review","author":"Wang","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0520","doi-asserted-by":"crossref","first-page":"32869","DOI":"10.1038\/s41598-025-14731-4","article-title":"A novel HP\u03b2CD-Cu (DDC) 2 delivery system in patient derived orthotopic xenograft targeting MGMT-mediated temozolomide resistance in glioblastoma","volume":"15","author":"Suhail","year":"2025","journal-title":"Sci. Rep."},{"issue":"24","key":"10.1016\/j.bcp.2026.118058_b0525","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.3390\/cells11244063","article-title":"Intersections of ubiquitin-proteosome system and autophagy in promoting growth of glioblastoma multiforme: challenges and opportunities","volume":"11","author":"Visintin","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.bcp.2026.118058_b0530","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/onc.2009.343","article-title":"Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells","volume":"29","author":"Zhu","year":"2010","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0535","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12645-025-00334-1","article-title":"Engineered exosomes: advanced nanocarriers for targeted therapy and drug delivery in hematological malignancies","volume":"16","author":"Rahgoshay","year":"2025","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.bcp.2026.118058_b0540","unstructured":"Bezze, A., Three-dimensional model to predict cell\u2010mediated nanoparticles drug delivery for Glioblastoma treatment. 2021."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0545","doi-asserted-by":"crossref","first-page":"37437","DOI":"10.1038\/s41598-025-21272-3","article-title":"Modulation of the blood\u2013brain barrier permeability by patient-derived glioblastoma stem cell secretome","volume":"15","author":"Sica","year":"2025","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.bcp.2026.118058_b0550","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1039\/C6CS00592F","article-title":"Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment","volume":"46","author":"Dai","year":"2017","journal-title":"Chem. Soc. Rev."},{"issue":"12","key":"10.1016\/j.bcp.2026.118058_b0555","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1039\/D2BM00181K","article-title":"Nanoparticle based medicines: approaches for evading and manipulating the mononuclear phagocyte system and potential for clinical translation","volume":"10","author":"Mills","year":"2022","journal-title":"Biomater. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2026.118058_b0560","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70386","article-title":"Exosome\u2010Based Therapeutics: a Natural solution to Overcoming the Blood\u2013Brain Barrier in Neurodegenerative Diseases","volume":"6","author":"Sun","year":"2025","journal-title":"MedComm"},{"issue":"6","key":"10.1016\/j.bcp.2026.118058_b0565","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1021\/acsabm.4c01956","article-title":"Advancements in using Polymeric Nanoparticles for Blood\u2013Brain Barrier Penetration in Neurological Disorders","volume":"8","author":"Wu","year":"2025","journal-title":"ACS Appl. Bio Mater."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0570","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/uog.18945","article-title":"Counting ovarian antral follicles by ultrasound: a practical guide","volume":"51","author":"Coelho Neto","year":"2018","journal-title":"Ultrasound Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0575","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12951-022-01610-7","article-title":"Overcoming the blood\u2013brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches","volume":"20","author":"Mitusova","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118058_b0580","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1046\/j.1469-7580.2002.00047_13.x","article-title":"Astrocyte\u2013endothelial interactions and blood\u2013brain barrier permeability","volume":"200","author":"Abbott","year":"2002","journal-title":"J. Anat."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0585","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2026.118058_b0590","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/ph18030385","article-title":"Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies","volume":"18","author":"Bedeschi","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bcp.2026.118058_b0595","doi-asserted-by":"crossref","DOI":"10.3389\/fphy.2025.1723329","article-title":"Molecular and biophysical remodeling of the blood\u2013brain barrier in glioblastoma: mechanistic drivers of tumor\u2013neurovascular crosstalk","volume":"13","author":"Abikenari","year":"2025","journal-title":"Front. Phys."},{"issue":"6","key":"10.1016\/j.bcp.2026.118058_b0600","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3390\/biomedicines13061452","article-title":"Emerging Chemotherapy Targets: Insights from advances in Glioma Treatment","volume":"13","author":"Rezk","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0605","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12645-025-00342-1","article-title":"Regulation of oxidative stress and inflammation caused by drug accumulation in the TME based on EPR-passive strategy and active targeting","volume":"16","author":"Deng","year":"2025","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.bcp.2026.118058_b0610","first-page":"191","article-title":"Stimuli-Responsive Nanocarriers in Breast Cancer. Nano Theragnostics in Breast Cancer: advances, challenges, and Future","author":"Bappy","year":"2026","journal-title":"Prospects"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0615","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/20415990.2024.2415281","article-title":"Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies","volume":"16","author":"Dhiman","year":"2025","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.bcp.2026.118058_b0620","article-title":"Engineering neuroimmune regulation: biomaterial and nanotechnology platforms for neuropathology diagnosis and targeted immunomodulation","volume":"16","author":"Jackson","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118058_b0625","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202409522","article-title":"Critical challenges of Intravenous Nanomaterials Crossing the Blood\u2010Brain Barrier: from Blood to Brain","volume":"35","author":"Luo","year":"2025","journal-title":"Adv. Funct. Mater."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0630","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202500115","article-title":"Nanobiotechnology\u2010Based Approaches for Targeted Glioma Therapy","volume":"6","author":"Li","year":"2026","journal-title":"Adv. NanoBiomed Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118058_b0635","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3390\/pharmaceutics15051362","article-title":"Lactoferrin and nanotechnology: the potential for cancer treatment","volume":"15","author":"Tran","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.bcp.2026.118058_b0640","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1021\/acs.molpharmaceut.4c01327","article-title":"New Trends in Brain shuttle Peptides","volume":"22","author":"Prades","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2026.118058_b0645","first-page":"169","article-title":"Targeting TRIM25 as a Therapeutic Strategy to Enhance Ferroptosis in","volume":"321","author":"Zhu","year":"2025","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bcp.2026.118058_b0650","doi-asserted-by":"crossref","DOI":"10.1093\/intbio\/zyaf003","article-title":"Role of RGD-binding Integrins in ovarian cancer progression, metastasis and response to therapy","volume":"17","author":"Ranga","year":"2025","journal-title":"Integr. Biol."},{"issue":"44","key":"10.1016\/j.bcp.2026.118058_b0655","doi-asserted-by":"crossref","first-page":"49454","DOI":"10.1021\/acsami.2c11284","article-title":"Upconversion nanoparticle-based cell membrane-coated cRGD peptide bioorthogonally labeled nanoplatform for glioblastoma treatment","volume":"14","author":"Mo","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"7","key":"10.1016\/j.bcp.2026.118058_b0660","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3390\/pharmaceutics15071999","article-title":"Cell-penetrating and targeted peptides delivery systems as potential pharmaceutical carriers for enhanced delivery across the blood\u2013brain barrier (BBB)","volume":"15","author":"Ghorai","year":"2023","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.bcp.2026.118058_b0665","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3390\/pharmaceutics17050661","article-title":"Advancing Brain Targeting: Cost-Effective Surface-Modified Nanoparticles for Faster Market Entry","volume":"17","author":"Gomes","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2026.118058_b0670","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.828093","article-title":"Endothelial transcytosis in acute lung injury: emerging mechanisms and therapeutic approaches","volume":"13","author":"Jones","year":"2022","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0675","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1038\/s41467-025-58746-x","article-title":"Allosteric targeted drug delivery for enhanced blood-brain barrier penetration via mimicking transmembrane domain interactions","volume":"16","author":"Tang","year":"2025","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2026.118058_b0680","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3390\/pharmaceutics17030280","article-title":"Trojan Horse delivery strategies of Natural Medicine Monomers: challenges and Limitations in improving Brain Targeting","volume":"17","author":"Lei","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2026.118058_b0685","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2025.1644633","article-title":"Strategies for delivering drugs across the blood-brain barrier for the treatment of neurodegenerative diseases","volume":"5","author":"Zhang","year":"2025","journal-title":"Front. Drug Delivery"},{"key":"10.1016\/j.bcp.2026.118058_b0690","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.2147\/IJN.S502144","article-title":"Advancements in Cell Membrane-Derived Biomimetic Nanotherapeutics for Breast Cancer","author":"Zeng","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bcp.2026.118058_b0695","article-title":"Recent Breakthroughs in Exosome-based Drug delivery: a Comprehensive Review for Cancer Therapy","author":"Shah","year":"2025","journal-title":"Cancer Biother. Radiopharm."},{"issue":"9","key":"10.1016\/j.bcp.2026.118058_b0700","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1080\/03639045.2025.2530161","article-title":"Engineering pH-responsive niosomes with ergosterol and CHEMS for controlled carfilzomib release: insights from in vitro and in vivo studies","volume":"51","author":"Hajinezhad","year":"2025","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0705","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s42004-025-01491-5","article-title":"Towards precision medicine using biochemically triggered cleavable conjugation","volume":"8","author":"Parshad","year":"2025","journal-title":"Communications Chemistry"},{"issue":"6","key":"10.1016\/j.bcp.2026.118058_b0710","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3390\/pharmaceutics14061189","article-title":"Drug delivery systems in the development of novel strategies for glioblastoma treatment","volume":"14","author":"El Kheir","year":"2022","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.bcp.2026.118058_b0715","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202300161","article-title":"Next generation of brain cancer nanomedicines to overcome the blood\u2013brain barrier (BBB): Insights on transcytosis, perivascular tumor growth, and BBB models","volume":"6","author":"Bor","year":"2023","journal-title":"Advanced Therapeutics"},{"issue":"6","key":"10.1016\/j.bcp.2026.118058_b0720","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3390\/cancers15061879","article-title":"The extracellular matrix in glioblastomas: a glance at its structural modifications in shaping the tumoral microenvironment\u2014a systematic review","volume":"15","author":"Marino","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.bcp.2026.118058_b0725","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1152\/physrev.00037.2011","article-title":"Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer","volume":"92","author":"Wiig","year":"2012","journal-title":"Physiol. Rev."},{"issue":"6","key":"10.1016\/j.bcp.2026.118058_b0730","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/cells14060437","article-title":"The Role of Hypoxia-Inducible Factor-1\u03b1 (HIF-1\u03b1) in the Progression of Ovarian Cancer: Perspectives on Female Infertility","volume":"14","author":"Rahman","year":"2025","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.bcp.2026.118058_b0735","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1096\/fj.02-0088com","article-title":"Rapid endo\u2010lysosomal escape of poly (DL\u2010lactide\u2010coglycolide) nanoparticles: implications for drug and gene delivery","volume":"16","author":"Panyam","year":"2002","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2026.118058_b0740","doi-asserted-by":"crossref","unstructured":"Karthika, C. and R. Sureshkumar, P-glycoprotein efflux transporters and its resistance its inhibitors and therapeutic aspects, in Biomarkers and bioanalysis overview. 2020, IntechOpen.","DOI":"10.5772\/intechopen.90430"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0745","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1021\/acsmeasuresciau.4c00062","article-title":"Revolutionizing cancer immunotherapy: emerging nanotechnology-driven drug delivery systems for enhanced therapeutic efficacy","volume":"5","author":"Theivendren","year":"2024","journal-title":"ACS Measurement Science Au"},{"issue":"4","key":"10.1016\/j.bcp.2026.118058_b0750","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.7150\/thno.117691","article-title":"Tissue-type differences in Focused Ultrasound and Microbubble-mediated Drug delivery to the Brain Exist at Vessel Level","volume":"16","author":"De Maio","year":"2026","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.bcp.2026.118058_b0755","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.7150\/thno.69682","article-title":"Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy","volume":"12","author":"Upton","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0760","doi-asserted-by":"crossref","first-page":"18953","DOI":"10.1038\/srep18953","article-title":"Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo","volume":"6","author":"Manton","year":"2016","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.bcp.2026.118058_b0765","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.3390\/ijms26125634","article-title":"Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: a Scoping Review","volume":"26","author":"Meleiro","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0770","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12935-025-04048-7","article-title":"Resveratrol-mediated suppression of glioblastoma and glioma: targeting apoptosis, differentiation, and stem cell dynamics","volume":"25","author":"Asemi","year":"2025","journal-title":"Cancer Cell Int."},{"issue":"8","key":"10.1016\/j.bcp.2026.118058_b0775","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12081822","article-title":"Current Non-Metal Nanoparticle-based Therapeutic Approaches for Glioblastoma Treatment","volume":"12","author":"Gawel","year":"2024","journal-title":"Biomedicines"},{"issue":"14","key":"10.1016\/j.bcp.2026.118058_b0780","doi-asserted-by":"crossref","DOI":"10.3390\/cells14141057","article-title":"Influence of Hypoxia on Tumor Heterogeneity, DNA Repair, and Cancer Therapy: from Molecular Insights to Therapeutic strategies","volume":"14","author":"Kunachowicz","year":"2025","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.bcp.2026.118058_b0785","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/15548627.2025.2589906","article-title":"Activation of chaperone-mediated autophagy suppresses glioblastoma by promoting wild-type IDH1\/isocitrate dehydrogenase 1 degradation","volume":"22","author":"Tang","year":"2026","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0790","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13619-025-00224-2","article-title":"Autophagy in adult stem cell homeostasis, aging, and disease therapy","volume":"14","author":"Zhao","year":"2025","journal-title":"Cell Regen"},{"key":"10.1016\/j.bcp.2026.118058_b0795","article-title":"Hydroxychloroquine Prevents High-altitude Cerebral Edema by Inhibiting Endothelial Claudin-5 Autophagic Degradation","author":"Xue","year":"2025","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bcp.2026.118058_b0800","doi-asserted-by":"crossref","unstructured":"Rahman, M.A., et al., Recent Update and Drug Target in Molecular and Pharmacological Insights into Autophagy Modulation in Cancer Treatment and Future Progress. Cells, 2023. 12(3).","DOI":"10.3390\/cells12030458"},{"issue":"18","key":"10.1016\/j.bcp.2026.118058_b0805","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.2174\/0115680266345188250304064600","article-title":"Natural Compounds and their Nano-formulations in Combating Autophagy-mediated Drug Resistance in Human Cancers","volume":"25","author":"Khan","year":"2025","journal-title":"Curr. Top. Med. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2026.118058_b0810","doi-asserted-by":"crossref","first-page":"e3167","DOI":"10.1038\/cddis.2017.520","article-title":"Bortezomib-induced miRNAs direct epigenetic silencing of locus genes and trigger apoptosis in leukemia","volume":"8","author":"Chu","year":"2017","journal-title":"Cell Death Dis."},{"issue":"15","key":"10.1016\/j.bcp.2026.118058_b0815","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70752","article-title":"Exploring the potential of Zein Nanoparticles in Personalised Cancer Therapy, Highlighting their Various Methodologies, applications and challenges","volume":"29","author":"Alharbi","year":"2025","journal-title":"J. Cell Mol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118058_b0820","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/2211738507666190321112237","article-title":"Co-delivery Nanosystems for Cancer Treatment: a Review","volume":"7","author":"Eftekhari","year":"2019","journal-title":"Pharm. Nanotechnol."},{"key":"10.1016\/j.bcp.2026.118058_b0825","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1061186X.2026.2613059","article-title":"Nanomedicines: an update of diagnostic and therapeutic applications in multiple cancers","author":"Shinde","year":"2026","journal-title":"J. Drug Target."},{"key":"10.1016\/j.bcp.2026.118058_b0830","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1584688","article-title":"Overcoming immunotherapy resistance in glioblastoma: challenges and emerging strategies","volume":"16","author":"Fu","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0835","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11033-025-11317-1","article-title":"Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application","volume":"53","author":"Zhang","year":"2025","journal-title":"Mol. Biol. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2026.118058_b0840","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7150\/ijbs.122418","article-title":"PTPN22 Dephosphorylates CBL to Inhibit PD-L1 Ubiquitination and Drive Immunosuppression in Renal Cell Carcinoma","volume":"22","author":"Jin","year":"2026","journal-title":"Int. J. Biol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2026.118058_b0845","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3390\/pharmaceutics17060682","article-title":"Synergistic cancer therapies enhanced by nanoparticles: advancing nanomedicine through multimodal strategies","volume":"17","author":"Mousavi-Kiasary","year":"2025","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.bcp.2026.118058_b0850","first-page":"513","article-title":"Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications","volume":"19","author":"Ortiz","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bcp.2026.118058_b0855","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/B978-0-443-26635-5.00041-9","article-title":"Therapeutics of bortezomib, carfilzomib, and ixazomib in proteases-induced cancer","author":"Gokce","year":"2025","journal-title":"Therapeutics of Natural and Synthetic Compounds in Protease-Induced Cancer"},{"issue":"21","key":"10.1016\/j.bcp.2026.118058_b0860","doi-asserted-by":"crossref","first-page":"11595","DOI":"10.3390\/ijms222111595","article-title":"Proteasome inhibitors and their pharmacokinetics, pharmacodynamics, and metabolism","volume":"22","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118058_b0865","unstructured":"Boccellato, C., Overcoming glioblastoma intractability: pre-clinical characterisation of TRAIL sensitisation by marizomib and novel treatment perspectives. 2022, Dissertation, Stuttgart, Universit\u00e4t Stuttgart, 2022."},{"issue":"7","key":"10.1016\/j.bcp.2026.118058_b0870","first-page":"1038","article-title":"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients","volume":"124","author":"Richardson","year":"2014","journal-title":"Blood, the Journal of the American Society of Hematology"},{"issue":"5","key":"10.1016\/j.bcp.2026.118058_b0875","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s43440-025-00739-0","article-title":"Marizomib in the therapy of brain tumors\u2014how far did we go and where do we stand?","volume":"77","author":"Kusaczuk","year":"2025","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bcp.2026.118058_b0880","unstructured":"Lo Buglio, G., Developing 3D In Vitro Tumor Models: Extracellular Matrix Remodeling by Collagenases to Increase Drug Efficacy. 2026."},{"issue":"suppl_3","key":"10.1016\/j.bcp.2026.118058_b0885","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/oxfordjournals.jac.a020890","article-title":"Pharmacodynamics to combat resistance","volume":"46","author":"Woodnutt","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bcp.2026.118058_b0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117302","article-title":"Overcoming standard-of-care resistance in glioblastoma using nanoparticle-based drug delivery targeting the autophagy pathway","author":"Rahman","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118058_b0895","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084153","article-title":"Crossing the Blood-Brain Barrier: advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology","volume":"23","author":"Hersh","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"29","key":"10.1016\/j.bcp.2026.118058_b0900","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202502315","article-title":"Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape","volume":"21","author":"Desai","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.bcp.2026.118058_b0905","doi-asserted-by":"crossref","first-page":"0120","DOI":"10.34133\/bmef.0120","article-title":"A Systematic Review of Toxicity, Biodistribution, and Biosafety in Upconversion Nanomaterials: critical Insights into Toxicity Mitigation strategies and Future Directions for Safe applications","volume":"6","author":"Khan","year":"2025","journal-title":"BME Front."},{"key":"10.1016\/j.bcp.2026.118058_b0910","first-page":"1","article-title":"Innovative polymer-based therapeutics targeting inflammation for responsive drug delivery in disease treatment","author":"Lipsi","year":"2025","journal-title":"Inflammopharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2026.118058_b0915","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr8841","article-title":"Peptide-drug conjugates repolarize glioblastoma-associated macrophages to resensitize chemo-immunotherapy of glioblastoma","volume":"11","author":"Li","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bcp.2026.118058_b0920","article-title":"Peripheral neuropathy: a review","author":"Mauermann","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10237-025-02028-4","article-title":"Biomechanical modeling of glioblastoma progression: a comprehensive review from classic mathematical frameworks to data-driven strategies: M. Ghahramani and O","volume":"25","author":"Ghahramani","year":"2026","journal-title":"Bavi. Biomechanics and Modeling in Mechanobiology"},{"key":"10.1016\/j.bcp.2026.118058_b0930","article-title":"Current Modeling Approaches for Drug delivery to the Central nervous","author":"Goraya","year":"2026","journal-title":"System"},{"issue":"7","key":"10.1016\/j.bcp.2026.118058_b0935","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.7150\/thno.123550","article-title":"Engineering polysaccharide nanoplatforms for glioblastoma theranostics: Bridging targeted therapy and advanced imaging","volume":"16","author":"Wang","year":"2026","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0940","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s12951-025-03415-w","article-title":"Advances in brain-targeted delivery strategies and natural product-mediated enhancement of blood\u2013brain barrier permeability","volume":"23","author":"Liu","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118058_b0945","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1021\/acs.molpharmaceut.5c00474","article-title":"Drug delivery systems for overcoming physical barriers in cancer therapy","volume":"22","author":"Yi","year":"2025","journal-title":"Mol. Pharm."},{"issue":"39","key":"10.1016\/j.bcp.2026.118058_b0950","doi-asserted-by":"crossref","first-page":"18274","DOI":"10.1039\/D4NR02795G","article-title":"Unleashing nanotechnology to redefine tumor-associated macrophage dynamics and non-coding RNA crosstalk in breast cancer","volume":"16","author":"Patni","year":"2024","journal-title":"Nanoscale"},{"issue":"7","key":"10.1016\/j.bcp.2026.118058_b0955","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202403107","article-title":"Navigating tumor microenvironment barriers with nanotherapeutic strategies for targeting metastasis","volume":"14","author":"Thomas","year":"2025","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.bcp.2026.118058_b0960","series-title":"Commercial Scale Production of Nanomedicines","first-page":"1","article-title":"Challenges for commercial translation of nanomedicines: from lab scale to production scale","author":"Khopade","year":"2025"},{"issue":"5","key":"10.1016\/j.bcp.2026.118058_b0965","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3390\/pharmaceutics17050550","article-title":"A Review on the Stability challenges of Advanced Biologic Therapeutics","volume":"17","author":"Sarvepalli","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2026.118058_b0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.tibtech.2025.12.003","article-title":"Translational pathways for MSC secretome therapies: from bioprocessing to delivery","author":"Rossello-Gelabert","year":"2026","journal-title":"Trends in Biotechnol."},{"key":"10.1016\/j.bcp.2026.118058_b0975","series-title":"Nanomedicine and Nutrigenomics","first-page":"217","article-title":"Regulatory landscape and challenges in nanomedicine","author":"Kumar","year":"2026"},{"issue":"3","key":"10.1016\/j.bcp.2026.118058_b0980","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/neuroglia6030028","article-title":"Nanomedicine-based advances in brain cancer treatment\u2014A review","volume":"6","author":"Loushambam","year":"2025","journal-title":"Neuroglia"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0985","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-025-05241-4","article-title":"The current status of immune checkpoint inhibitors in pediatric CNS tumors: a systematic review with a representative case of CMMRD-associated glioma","volume":"176","author":"Gulsuna","year":"2026","journal-title":"J. Neurooncol"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b0990","doi-asserted-by":"crossref","first-page":"123","DOI":"10.7150\/thno.117363","article-title":"Neutrophil-based delivery platforms: from natural mechanisms to engineered therapeutics","volume":"16","author":"Li","year":"2026","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2026.118058_b0995","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.2147\/DDDT.S530999","article-title":"Harnessing organoid platforms for nanoparticle drug development","author":"Chen","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcp.2026.118058_b1000","article-title":"Near-Infrared Fluorescence Probes with Nanoparticles: Transforming Cancer Imaging and Biomedical Diagnostics","author":"Javaid","year":"2025","journal-title":"Techniques"},{"key":"10.1016\/j.bcp.2026.118058_b1005","doi-asserted-by":"crossref","DOI":"10.1039\/D4PM00263F","article-title":"Comprehensive review on glioblastoma: nanotechnology, immunotherapy and combined therapeutic approaches","author":"Dhiman","year":"2025","journal-title":"RSC Pharmaceutics"},{"issue":"5","key":"10.1016\/j.bcp.2026.118058_b1010","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3390\/ijms25052529","article-title":"Glioblastoma therapy: past, present and future","volume":"25","author":"Obrador","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.bcp.2026.118058_b1015","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1039\/D3NR06131K","article-title":"Nanomedicine as a multimodal therapeutic paradigm against cancer: on the way forward in advancing precision therapy","volume":"16","author":"Sandbhor","year":"2024","journal-title":"Nanoscale"},{"issue":"2","key":"10.1016\/j.bcp.2026.118058_b1020","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/antiox12020428","article-title":"Recent advances in cellular signaling interplay between redox metabolism and autophagy modulation in cancer: an overview of molecular mechanisms and therapeutic interventions","volume":"12","author":"Rahman","year":"2023","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.bcp.2026.118058_b1025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","article-title":"Glioblastoma at the crossroads: current understanding and future therapeutic horizons","volume":"10","author":"Singh","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.118058_b1030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.phrs.2017.05.004","article-title":"Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy","volume":"126","author":"Yang","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"17","key":"10.1016\/j.bcp.2026.118058_b1035","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.3390\/cancers13174255","article-title":"Tumor-associated microglia and macrophages in the glioblastoma microenvironment and their implications for therapy","volume":"13","author":"Andersen","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.bcp.2026.118058_b1040","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.3390\/ijms25116219","article-title":"Tumor-homing peptides as crucial component of magnetic-based delivery systems: recent developments and pharmacoeconomical perspective","volume":"25","author":"Milewska","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118058_b1045","series-title":"Nanotherapy for Brain Tumor Drug Delivery","first-page":"205","article-title":"Focused ultrasound-mediated blood-brain barrier disruption for enhanced drug delivery to brain tumors","author":"Anastasiadis","year":"2020"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:36:02Z","timestamp":1783920962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226003916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":209,"alternative-id":["S0006295226003916"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118058","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticle-Based delivery of proteasome inhibitors for glioblastoma Therapy: Strategies to overcome Blood-Brain barrier and therapeutic resistance","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118058"}}